Enable JavaScript to visit this website.
Skip directly to content



July 18, 2019 – Kirkland, QC – Pfizer Canada provided the following update regarding supply of EpiPen auto-injectors in Canada today:

“While there has been stable supply of both formats of EpiPen auto-injectors in Canada in 2019 to date, Pfizer Canada is projecting that we may experience supply constraints of the EpiPen 0.3 mg format over the coming months.

We can confirm that product is still routinely shipping to Canada.  However, out of abundance of caution, and after informing Health Canada, we have begun to preventatively manage available EpiPen 0.3 mg supply through measured national allocation to wholesalers.

We fully recognize the criticality of EpiPen auto-injectors to patients and physicians and are working hard to ensure consistent supply.   This allocation is intended to support the provision of EpiPen 0.3 mg auto-injectors to patients across the country and avoid a stock-out during the upcoming high demand back to school season.

At this time, this situation only applies to EpiPen auto-injectors in the 0.3 mg format and there is supply of EpiPen Jr (0.15 mg) auto-injectors at wholesalers, distributors and at pharmacies across the country.” 



For additional questions:

Patients can visit www.epipen.ca or call 1-877-EPIPEN1.

Healthcare professionals with an inquiry of a medical nature related to EpiPen auto-injectors, please contact Pfizer’s Medical Information Group at 1-800-463-6001; www.pfizermedicalinformation.ca

If you are a member of the media, please call: Pfizer Canada Media Relations at 1-866-9Pfizer (1-866-973-4937) email: [email protected].